Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19253697 | 1.00 | MAPT (0.31) | MAPTMEN1ALOX15ALOX12HBB | |
| SCHEMBL19253599 | 0.77 | HPGD (0.35) | MAPTMEN1ALOX15ALOX12HBB | |
| SCHEMBL19253667 | 0.77 | HPGD (0.35) | MAPTMEN1ALOX15ALOX12HBB | |
| SCHEMBL30623726 | 0.67 | MAPT (0.40) | MAPTHPGDHTT | |
| SCHEMBL16102421 | 0.66 | ALDH1A1 (0.33) | MAPTMEN1ALOX15ALOX12HBB | |
| SCHEMBL19253755 | 0.65 | CTSL (0.37) | HPGDHTT | |
| SCHEMBL3830652 | 0.63 | HTT (0.39) | MAPTMEN1ALOX15ALOX12HBB | |
| SCHEMBL3715027 | 0.62 | OPRM1 (0.39) | MEN1KMT2AHPGDOPRM1OPRD1 | |
| SCHEMBL25331875 | 0.61 | ALDH1A1 (0.40) | MAPTMEN1KMT2AHSD17B10HPGD | |
| SCHEMBL25331750 | 0.61 | ALDH1A1 (0.40) | MAPTMEN1KMT2AHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | MAPT 4153/4885MEN1 2582/4885ALOX15 625/4885 |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | JAK1, JAK2, JAK3 | MAPT 4153/4885MEN1 2582/4885ALOX15 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.